Immunizations for Adolescents (IMA)

By working together, we can improve health outcomes for your patients, our members. The Healthcare Effectiveness Data and Information Set (HEDIS®) helps us measure many aspects of performance. This tip sheet provides key details of the HEDIS measure for immunizations for adolescents.

What is the measure?

This measure assesses the percentage of 13-year-old members who have had the following by their 13th birthday:

- One dose of meningococcal vaccine
 - o On or between their 11th and 13th birthday
 - Anaphylaxis due to the meningococcal vaccine any time on or before their 13th birthday
- One dose of tetanus, diphtheria toxoids and acellular pertussis (Tdap) vaccine
 - o On or between their **10**th and **13**th birthday
 - Anaphylaxis due to tetanus, diphtheria, or pertussis vaccine any time on or before their 13th birthday
 - Encephalitis due to the tetanus, diphtheria, or pertussis vaccine any time on or before their 13th birthday
- Two or three doses of human papillomavirus (HPV) vaccine
 - Two HPV doses 146 days apart OR three HPV doses with different dates of service between their 9th and 13th birthday
 - o Anaphylaxis due to the HPV vaccine any time on or before their 13th birthday

Acceptable Documents

Documentation must include the vaccination date(s) with at least one of the following:

- Certificate of immunization
- Progress note/Office note/Subjective, Objective, Assessment and Plan (SOAP) note
 - o Date of encounter or office visit note must be on or before the 13th birthday
- Diagnostic report
- Problem list

HEDIS Measure: Immunizations for Adolescents (IMA) (continued)

Documentation Details

Documentation must include:

- A note indicating the name of the specific antigen and the date of the immunization
- An immunization certificate prepared by an authorized health care provider or agency which must include the specific dates and types of immunizations administered

Continued on next page

Documentation Details

- For meningococcal conjugate, do not count meningococcal polysaccharide or serogroup B meningococcal recombinant (MenB) vaccines.
- Generic header or general documentation indicating the meningococcal vaccine was administered meets criteria.
- Only the quadrivalent meningococcal vaccine meets criteria.
- Immunizations documented using a generic header of Tdap/Td can be counted as evidence of Tdap vaccine.

Exclusions

- Members in hospice or using hospice services anytime during the measurement year
- Members who died any time during the measurement year

Codes

Meningococcal CPT: 90619, 90733 -- 90734

Tdap CPT: 90715

HPV CPT: 90649 -- 90651

Anaphylactic reaction to vaccination, initial

encounter

ICD-10: T80.52XA

Anaphylactic reaction ICD-10: T80.52XD

to vaccination, subsequent

encounter

Anaphylactic reaction ICD-10: T80.52XS to vaccination, sequela

Hospice CPT: 99377 -- 99378,

Content reproduced with permission from HEDIS® MY 2023 Volume 2: Technical Specifications for Health Plans by the National Committee for Quality Assurance (NCQA). HEDIS measures and specifications are not clinical guidelines and do not establish a standard of medical care. NCQA makes no representations, warranties, or endorsement about the quality of any organization or physician that uses or reports performance measures and NCQA has no liability to anyone who relies on such measures or specifications. Limited proprietary coding sets are contained in the specifications for convenience, and users should obtain all necessary licenses from the owners of the code sets. NCQA disclaims all liability for use or accuracy of any coding contained in the specifications. To purchase copies of the publication, including the full measures and specifications, visit ncqa.org/publications.

99273 0323R 2